Vermillion Q2 Revenues Up 33 Percent, OVA1 Sales Down | GenomeWeb

NEW YORK (Genomeweb) – Vermillion reported today that its second quarter revenues rose 33 percent from Q2 2015, after commencing operations of its Aspira IVD diagnostics specialized laboratory provider.

For the quarter ended June 30, the company reported revenues of $709,000, up from $535,000 a year ago. Product revenue rose to $554,000, up slightly from $535,000 in Q2 2015. The company also posted $155,000 in service revenue, compared to none in the year-ago quarter.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.